Clinical Trial Update: Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of ABBV-744 alone or in combination with oral ruxolitinib or navitoclax in adult patients with myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• ABBV-744 (ABBV-744)
• Jakafi (ruxolitinib)
• Navitoclax (navitoclax)

Snippet

Sponsor: AbbVie | Conditions: Myelofibrosis (MF) | Phase 1 | Status: ACTIVE_NOT_RECRUITING